Pembrolizumab plus lenvatinib as first-line therapy for advanced non-clear-cell renal cell carcinoma (KEYNOTE-B61): a single-arm, multicentre, phase 2 trial

作者：Laurence Albigès, Howard Gurney, Vagif Atduev, Cristina Suárez, Miguel Ángel Climent, David Pook, Piotr Tomczak, Philippe Barthélémy, Jae‐Lyun Lee, V.P. Stus, Thomas Ferguson, Paweł Wiechno, Erhan Gökmen, Louis Lacombe, Craig Gedye, Rodolfo F. Perini, Manish Sharma, Xiang Peng, Chung‐Han Lee · 发表于：The Lancet Oncology · 年份：2023 · DOI：10.1016/s1470-2045(23)00276-0 · 被引用次数：157 · 研究领域：Renal cell carcinoma treatment、Cancer Immunotherapy and Biomarkers、Ferroptosis and cancer prognosis